EastPharma Ltd. reported earnings results for the six months ended June 30, 2017. According to IFRS results, revenue in the first half of 2017 was USD 113.8 million, down 8.5% from the same period in 2016. The company’s sales decrease in US dollar terms was mainly due to depreciation of Turkish Lira against hard currencies. EBITDA in first half of 2017 was USD 27.6 million against USD 34.1 million in the first half of 2016.